Changes in the Executive Board of Octapharma - Kim Björnstrup, Vice Chairman of Octapharma is leaving the company as of 21.10.20

Changes in the Executive Board of Octapharma - Kim Björnstrup, Vice Chairman of Octapharma is leaving the company as of 21.10.2010
21.10.2010
 
In mutual consent, Mr. Kim Björnstrup has resigned from his position as Vice Chairman of the Octapharma Group with effect as of October 21st, 2010.

Wolfgang Marguerre, Chairman of Octapharma, states: "I appreciate and thank him for his valuable and excellent contribution to our business endeavors throughout the past 18 years. I wish him a successful continuation of his career and good luck for his future."

 

About Octapharma

Octapharma is a biopharmaceutical company. It is dedicated to the safe and optimal usage of human proteins. Octapharma products are state-of-the-art within treatment of haemophilia, immune diseases, volume expansion and plasma transfusions. The company was founded in 1983 and since then has grown to over 4,000 employees. Nowadays it has 37 subsidiaries and representative offices and is making sales in over 80 countries. Turnover in 2009 was Euro 1,008 million.

For more information about the company please click here.

 

Contact:
Octapharma AG
Corporate Communications
Corinne Landolt
Tel.: +41 (55) 451 21 36
Corinne.Landoltanti spam [email protected] spam bot.com

Seidenstrasse 2
CH-8853 Lachen
Switzerland

 

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.